Pancreatic cancer is an increasingly lethal cancer and is often diagnosed at an advanced stage. Pancreatic ductal adenocarcinoma (PDAC) accounts for more than 90% of all pancreatic malignant tumors and is known as the "king of cancers". The degree of malignancy is very high, making diagnosis and treatment difficult. This is because pancreatic ductal adenocarcinoma tissue contains a large amount of fibrous tissue in addition to ductal epithelial cell components. The existence of fibrous tissue results in poor blood supply for pancreatic cancer, making it difficult for chemotherapy drugs to enter, so the treatment effect is not ideal. So there is a need to develop new and more effective treatments to cure this disease.
Pancreatic Cancer Antibodies We Offer
Antibodies can be used to target cancer cells and prevent tumor growth and progression. Antibodies have been widely used in malignant tumor research, such as pancreatic cancer, breast cancer, colon cancer, non-small cell lung cancer, etc. Clinical studies have shown that antibody therapy can not only effectively kill focus cells, but also activate the human immune system to improve the body's defense against cancer, while reducing treatment side effects and improving patient survival rates. The essence of antibody therapy is to use specific monoclonal antibodies synthesized in vitro to achieve the purpose of treatment by identifying, binding and eliminating disease-related antigens or disease cells expressing antigens. Alfa Cytology has extensive experience in pancreatic cancer research and can provide you with antibody products suitable for your research project.
Alfa Cytology is committed to providing customers with antibody products with strong targeting, high stability, and obvious effects for pancreatic cancer research. We can recommend the best antibody options based on our customers' needs. If you are interested in our products, please contact us for more details.
HJC0149
Catalog No.: PC0163
Description: HJC0149 is a potent and orally active inhibitor of signal transducer and activator of transcription 3 (STAT3).
I-OMe-Tyrphostin AG 538
Catalog No.: PC0164
Description: I-OMe-Tyrphostin AG 538 (I-OMe-AG 538) is a specific inhibitor of IGF-1R that inhibits IGF-1R-mediated signaling and preferentially produces cytotoxicity on nutrient-starved PANC1 cells.
ZZW-115
Catalog No.: PC0165
Description: ZZW-115 is a potent NUPR1 inhibitor that induces tumor cell death via necroptosis and apoptosis.
ZZW-115 hydrochloride
Catalog No.: PC0166
Description: ZZW-115 hydrochloride is a potent NUPR1 inhibitor that induces tumor cell death via necroptosis and apoptosis.
AG-270
Catalog No.: PC0167
Description: AG-270 is an allosteric, noncompetitive, first-in-class, reversible and orally active MAT2A inhibitor, with an IC50 of 14 nM.
Fimaporfin
Catalog No.: PC0168
Description: Fimaporfin (TPCS2a) is an endosomal/lysosomal-localizing photosensitizer.
Sulfopin
Catalog No.: PC0169
Description: Sulfopin (PIN1-3) is a highly selective covalent inhibitor of Pin1 that blocks Myc-driven tumors in vivo. The peptidylprolyl isomerase Pin1 is used in cancer to activate oncogenes and inactivate tumor suppressors.
c-Myc inhibitor 8
Catalog No.: PC0170
Description: c-Myc inhibitor 8 is a c-Myc inhibitor that can effectively inhibit the cell viability of a variety of cancer cells. c-Myc inhibitor 8 inhibits human prostate and lung cancer growth in mouse models.
AP1153 aptamer sodium
Catalog No.: PC0171
Description: AP1153 aptamer sodium is a DNA aptamer that specifically binds to the cholecystokinin receptor CCKBR (Kd: ~15 pM) but does not activate CCKBR-related signaling pathways. The sodium AP1153 aptamer is internalized by pancreatic ductal adenocarcinoma cells (PDAC) in a receptor-mediated manner and can be bioconjugated to fluorescent nanoparticle surfaces to facilitate in vivo delivery of nanoparticles to PDAC tumors.
DCLK1-IN-1
Catalog No.: PC0172
Description: DCLK1-IN-1 is a selective, oral bioavailability in vivo-compatible chemical probe of the doublecortin like kinase 1 (DCLK1 kinase) domain. DCLK1-IN-1 inhibits DCLK1 and DCLK2 kinases (IC50: DCLK1=9.5/57.2 nM and DCLK2=31/103 nM in binding and kinase assay, respectively). DCLK1-IN-1 shows low toxicity, and can investigate DCLK1 biology and establish its role in cancer, like DCLK1+ pancreatic ductal adenocarcinoma (PDAC).
Clobenpropit dihydrobromide
Catalog No.: PC0173
Description: Clobenpropit dihydrobromide is a potent histamine H3R antagonist/inverse agonist and partial agonist of H4 receptors (Ki 13 nM). Clobenpropit dihydrobromide also binds to serotonin 5-HT3 receptors and α2A/α2C adrenergic receptors. Chlorprofen dihydroborb increases apoptosis.
Almorexant
Catalog No.: PC0174
Description: Almorexant (ACT 078573) is an orally active, potent, and competitive dual orexin receptor antagonist that reversibly blocks signaling by orexin-A and orexin-B peptides. Almorexant completely blocks intracellular Ca2+ signaling pathways. Almorexant stimulates caspase-3 activity and induces apoptosis in AsPC-1 cells.
Almorexant hydrochloride
Catalog No.: PC0175
Description: Almorexant (ACT 078573) hydrochloride is an orally active, potent, and competitive dual orexin receptor antagonist that reversibly blocks signaling by orexin-A and orexin-B peptides. Almorexant hydrochloride completely blocks the intracellular Ca2+ signaling pathway. Almorexant hydrochloride stimulates caspase-3 activity and induces apoptosis in AsPC-1 cells.
Zn-DPA-maytansinoid conjugate 1
Catalog No.: PC0176
Description: Zn-DPA-maytansinoid conjugate 1 is a small molecule-based maytansinoid conjugate targeting immune checkpoint. Zn-DPA-maytansinoid conjugate 1 induces lasting regression of tumor growth and rejuvenates tumor microenvironment (TME) to an “inflamed hot tumor”.
Tetramethylcurcumin
Catalog No.: PC0177
Description: Tetramethylcurcumin (FLLL31), derived from curcumin, specifically suppresses the phosphorylation of STAT3 by binding selectively to Janus kinase 2 and the STAT3 Src homology-2 domain. Tetramethylcurcumin exhibits anti-inflammatory and anti-cancer effects.
O6-Benzylguanine
Catalog No.: PC0178
Description: O6-Benzylguanine is a guanine analogue and inhibitor of the DNA repair enzyme O6-alkylguanine-DNA alkyltransferase (MGMT/AGT). O6-benzylguanine acts as an AGT substrate and transfers its benzyl group to the AGT cysteine residue, thereby irreversibly inactivating AGT and preventing DNA repair. O6-benzylguanine induces tumor cell apoptosis.
SHP2-IN-9
Catalog No.: PC0179
Description: SHP2-IN-9 is a specific SHP2 inhibitor with enhanced blood-brain barrier permeability. SHP2-IN-9 inhibits SHP2-mediated cell signaling and cancer cell proliferation and inhibits cervical cancer tumor and glioblastoma growth in vivo.
GOT1 inhibitor-1
Catalog No.: PC0180
Description: GOT1 inhibitor-1, a tryptamine-based derivative, is a novel, potent, non-covalent, non-covalent glutamate oxaloacetate aminotransferase 1 (GOT1) inhibitor with an IC50 of 8.2 uM. GOT1 inhibitor-1 can be used in the study of pancreatic ductal adenocarcinoma (PDAC).
WBC100
Catalog No.: PC0181
Description: WBC100 (14-D-Valine-TPL) is a potent, selective, orally active c-Myc molecular glue degrader that targets the ubiquitin E3 ligase CHIP-mediated 26S proteasome pathway. WBC100 for the study of c-Myc-overexpressing tumors.
CU-T12-9
Catalog No.: PC0182
Description: CU-T12-9 is a specific TLR1/2 agonist with EC50 of 52.9 nM in HEK-Blue hTLR2 SEAP assay. CU-T12-9 activates both the innate and the adaptive immune systems. CU-T12-9 selectively activates the TLR1/2 heterodimer, not TLR2/6. CU-T12-9 signals through NF-κB and invokes an elevation of the downstream effectors TNF-α, IL-10, and iNOS.
